A phase III study to investigate the efficacy and safety of abrocitinib and dupilumab in comparison with placebo in adults with moderate-to-severe atopic dermatitis

被引：0

作者：

Thaci, D. ^{[1
]}

Bieber, T. ^{[2
]}

Simpson, E. L. ^{[3
]}

Silverberg, J. I. ^{[4
]}

Paul, C. ^{[5
,6
]}

Sinclair, R. ^{[7
]}

Pink, A. E. ^{[8
]}

Kataoka, Y. ^{[9
]}

Chu, C. -Y. ^{[10
,11
]}

DiBonaventura, M. ^{[12
]}

Rojo, R. ^{[13
]}

Antinew, J. ^{[13
]}

Ionita, I. ^{[13
]}

Forman, S. ^{[14
]}

Zdybski, J. ^{[15
]}

Biswas, P. ^{[12
]}

Malhotra, B. ^{[12
]}

Zhang, F. ^{[13
]}

Valdez, H. ^{[12
]}

机构：

[1] Univ Lubeck, Lubeck, Germany

[2] Univ Hosp Bonn, Bonn, Germany

[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[4] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA

[5] Toulouse Univ, Toulouse, France

[6] CHU Toulouse, Toulouse, France

[7] Sinclair Dermatol, East Melbourne, Vic, Australia

[8] Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England

[9] Osaka Habikino Med Ctr, Osaka, Japan

[10] Natl Taiwan Univ Hosp, Taipei, Taiwan

[11] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[12] Pfizer Inc, New York, NY USA

[13] Pfizer Inc, Groton, CT 06340 USA

[14] ForCare Clin Res, Tampa, FL USA

[15] Dermed Jacek Zdybski, Ostrowiec Swieztokrzyski, Poland

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 184卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

360

引用

页码：E72 / E73

页数：2